Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 41, Issue 4

Issues

Allele Frequencies for Glutathione S-Transferase and N-Acetyltransferase 2 Differ in African Population Groups and May Be Associated With Oesophageal Cancer or Tuberculosis Incidence

Craig H. Adams / Cedric J. Werely / Thomas C. Victor / Eileen G. Hoal / Gawie Rossouw / Paul D. van Helden
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.2003.090

Abstract

Glutathione S-transferase (GST) and arylamine N-acetyltransferase 2 (NAT2) metabolise many environmental and chemotherapeutic agents, which influence susceptibility to disease. Polymorphisms in these enzymes result in different host phenotypes and contribute to different disease profiles or responses to toxic or chemotherapeutic agents, depending on their frequency in different populations. GST and NAT2 polymorphisms were investigated in different population groups, including African populations, and a range of allelic frequencies have been observed. The GSTM1 null genotype frequency, reported in this paper in two South African ethnic groups, is the lowest reported (0.19–0.21). In contrast, these same groups have a high GSTT1 null frequency (0.41–0.54), which is considerably higher than in African-Americans, or other Africans. The GSTT1 null frequency is comparable to the Chinese, a population with a very high oesophageal cancer incidence, similar to that in the African group. The frequency of the GSTPi Val105 variant in the South African Xhosas was also high (0.53), differing significantly from the low frequency in other Africans. These variants could therefore be associated with high cancer susceptibility. In addition, the high proportion of NAT2 “fast” alleles may partially explain the high tuberculosis prevalence in South Africans, due to reduced isoniazid efficacy in the presence of rapid acetylation.

About the article

Published Online: 2005-06-01

Published in Print: 2003-04-25


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 41, Issue 4, Pages 600–605, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2003.090.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Hannah Simba, Helena Kuivaniemi, Vittoria Lutje, Gerard Tromp, and Vikash Sewram
Frontiers in Genetics, 2019, Volume 10
[2]
Jotam Pasipanodya and Tawanda Gumbo
Antimicrobial Agents and Chemotherapy, 2011, Volume 55, Number 1, Page 24
[3]
Joshua Agbemefa Kuleape, Emmanuel Ayitey Tagoe, Peter Puplampu, Evelyn Yayra Bonney, Osbourne Quaye, and Cinzia Ciccacci
PLOS ONE, 2018, Volume 13, Number 5, Page e0195954
[4]
Chun-Xia Yang
World Journal of Gastroenterology, 2005, Volume 11, Number 17, Page 2531
[5]
Marco Matejcic, DongPing Li, Natalie J. Prescott, Cathryn M. Lewis, Christopher G. Mathew, M. Iqbal Parker, and Amanda Ewart Toland
PLoS ONE, 2011, Volume 6, Number 12, Page e29366
[6]
Senthilkumar Pitchalu Kasthurinaidu, Thirumurugan Ramasamy, Jayachitra Ayyavoo, Dhvani Kirtikumar Dave, Divya Anantray Adroja, and Vince Grolmusz
PLOS ONE, 2015, Volume 10, Number 4, Page e0118660
[7]
Marco Matejcic and M. Iqbal Parker
Critical Reviews in Clinical Laboratory Sciences, 2015, Volume 52, Number 5, Page 211
[8]
[9]
Anita Sharma, Arvind Pandey, Shashi Sharma, Indranil Chatterjee, Ravi Mehrotra, Ashok Sehgal, and Joginder K. Sharma
Meta Gene, 2014, Volume 2, Page 134
[10]
Anatoly Samoylenko, Jubayer Al Hossain, Daniela Mennerich, Sakari Kellokumpu, Jukka Kalervo Hiltunen, and Thomas Kietzmann
Antioxidants & Redox Signaling, 2013, Volume 19, Number 17, Page 2157
[12]
Theresa Hahn, Eugenia Zhelnova, Lara Sucheston, Irina Demidova, Valery Savchenko, Minoo Battiwalla, Shannon L. Smiley, Christine B. Ambrosone, and Philip L. McCarthy
Biology of Blood and Marrow Transplantation, 2010, Volume 16, Number 6, Page 801
[13]
Ran Liu, Lihong Yin, Yuepu Pu, Yunhui Li, Geyu Liang, Juan Zhang, and Xiaobo Li
Journal of Toxicology and Environmental Health, Part A, 2010, Volume 73, Number 7, Page 471
[14]
Collet Dandara, Robea Ballo, and M. Iqbal Parker
Cancer Letters, 2005, Volume 225, Number 2, Page 275
[15]
Regina Devi Thoudam, Dhirendra Singh Yadav, Ashwani Kumar Mishra, Mishi Kaushal, Rakhshan Ihsan, Indranil Chattopadhyay, Pradeep Singh Chauhan, Jagannath Sarma, Eric Zomawia, Yogesh Verma, A. Nandkumar, Jagadish Mahanta, Rupkumar Phukan, Sujala Kapur, and Sunita Saxena
Genetic Testing and Molecular Biomarkers, 2010, Volume 14, Number 2, Page 163
[16]
Cedric J Werely, Peter R Donald, and Paul D van Helden
Personalized Medicine, 2007, Volume 4, Number 2, Page 123
[17]
Guilherme Suarez-Kurtz, Daniela D. Vargens, Claudio J. Struchiner, Luciana Bastos-Rodrigues, and Sergio D.J. Pena
Pharmacogenetics and Genomics, 2007, Volume 17, Number 9, Page 765
[18]
Valery V. Bakayev, Forozan Mohammadi, Moslem Bahadori, Mariam Sheikholslami, Arash Javeri, Mohammad R. Masjedi, and Ali A. Velayati
European Journal of Clinical Pharmacology, 2004, Volume 60, Number 7, Page 467

Comments (0)

Please log in or register to comment.
Log in